231 related articles for article (PubMed ID: 25467191)
1. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
Henk HJ; Woloj M; Shapiro M; Whiteley J
Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
[TBL] [Abstract][Full Text] [Related]
2. [Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].
Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):215-224. PubMed ID: 38716592
[No Abstract] [Full Text] [Related]
3. Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.
Ono T; Takahashi N; Kizaki M; Kawaguchi T; Suzuki R; Yamamoto K; Ohnishi K; Naoe T; Matsumura I
Cancer Sci; 2020 Oct; 111(10):3714-3725. PubMed ID: 33404088
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Zhang X; Xu N; Yang Y; Lin H; Liu B; Du X; Liu X; Liang R; Chen C; Huang J; Zhu H; Pan L; Wang X; Li G; Liu Z; Zhang Y; Liu Z; Hu J; Liu C; Li F; Yang W; Meng L; Han Y; Lin L; Zhao Z; Tu C; Zheng C; Bai Y; Zhou Z; Chen S; Qiu H; Yang L; Sun X; Sun H; Zhou L; Liu Z; Wang D; Guo J; Pang L; Zeng Q; Suo X; Zhang W; Zheng Y; Zhang Y; Li W; Jiang Q
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e257-e266. PubMed ID: 38461040
[TBL] [Abstract][Full Text] [Related]
5. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Jain AG; Gesiotto Q; Ball S; Nodzon L; Rodriguez A; Chan O; Padron E; Kuykendall A; Komrokji R; Sallman DA; Lancet JE; Pinilla-Ibarz J; Sweet K
Ann Hematol; 2024 Jun; 103(6):1941-1945. PubMed ID: 38634915
[TBL] [Abstract][Full Text] [Related]
6. [The Effect and Safety of Flumatinib in Patients with Chronic Myelogenous Leukemia Failed First-and Second-line Treatment].
Liu LY; Wei JF; Jia T; Mao JP; Cai ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):370-375. PubMed ID: 38660838
[TBL] [Abstract][Full Text] [Related]
7. Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia.
Klink AJ; Keating SJ; Brokars J; Feinberg B; Jabbour E
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):149-157. PubMed ID: 38135632
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.
Fujita S; Kasahara H; Kato J; Koda Y; Shiroshita K; Yamaguchi K; Okayama M; Abe R; Kikuchi T; Shimizu T; Mori T; Kataoka K; Okamoto S
Intern Med; 2024 Jun; 63(11):1549-1562. PubMed ID: 37899244
[TBL] [Abstract][Full Text] [Related]
9. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia.
Sönmez Ö; Özgür Yurttaş N; İhtiyaroğlu İ; Çakır HM; Atlı Z; Elverdi T; Salihoğlu A; Seyahi N; Ar MC; Öngören Ş; Başlar Z; Soysal T; Eşkazan AE
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):232-239. PubMed ID: 38281820
[TBL] [Abstract][Full Text] [Related]
10. [Discontinuation of tyrosine kinase inhibitors before epiphyseal closure leading to improved short stature in pediatric chronic myelogenous leukemia].
Fukui W; Ogura T; Azumi S; Ogata H; Kawaguchi K; Takachi T; Horikoshi Y; Uematsu A; Shimada H; Watanabe K
Rinsho Ketsueki; 2024; 65(3):175-179. PubMed ID: 38569862
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib: a novel, selective tyrosine kinase inhibitor.
Blay JY; von Mehren M
Semin Oncol; 2011 Apr; 38 Suppl 1(0 1):S3-9. PubMed ID: 21419934
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Santos FP; Kantarjian H; Fava C; O'Brien S; Garcia-Manero G; Ravandi F; Wierda W; Thomas D; Shan J; Cortes J
Br J Haematol; 2010 Aug; 150(3):303-12. PubMed ID: 20553275
[TBL] [Abstract][Full Text] [Related]
13. Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e138-e141. PubMed ID: 38195325
[TBL] [Abstract][Full Text] [Related]
14. Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.
Shieh MP; Mitsuhashi M; Lilly M
Clin Med Insights Oncol; 2011; 5():185-99. PubMed ID: 21792346
[TBL] [Abstract][Full Text] [Related]
15. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
Yoshida C; Yamaguchi H; Doki N; Murai K; Iino M; Hatta Y; Onizuka M; Yokose N; Fujimaki K; Hagihara M; Oshikawa G; Murayama K; Kumagai T; Kimura S; Najima Y; Iriyama N; Tsutsumi I; Oba K; Kojima H; Sakamaki H; Inokuchi K;
Int J Hematol; 2023 May; 117(5):694-705. PubMed ID: 36739328
[TBL] [Abstract][Full Text] [Related]
16. Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
Roy Moulik N; Keerthivasagam S; Pandey A; Agiwale J; Hegde K; Chatterjee G; Dhamne C; Prasad M; Chichra A; Srinivasan S; Mohanty P; Jain H; Shetty D; Tembhare P; Patkar N; Narula G; Subramanian PG; Banavali S
Br J Haematol; 2024 Apr; 204(4):1249-1261. PubMed ID: 38098201
[TBL] [Abstract][Full Text] [Related]
17. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
Mahon FX; Pfirrmann M; Dulucq S; Hochhaus A; Panayiotidis P; Almeida A; Mayer J; Hjorth-Hansen H; Janssen JJWM; Mustjoki S; Martinez-Lopez J; Vestergaard H; Ehrencrona H; Machová Poláková K; Olsson-Strömberg U; Ossenkoppele G; Berger MG; Etienne G; Dengler J; Brümmendorf TH; Burchert A; Réa D; Rousselot P; Nicolini FE; Hofmann WK; Richter J; Saussele S; ;
J Clin Oncol; 2024 Jun; 42(16):1875-1880. PubMed ID: 38471049
[No Abstract] [Full Text] [Related]
18. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Jabbour E; Kantarjian HM; O'Brien S; Shan J; Quintás-Cardama A; Garcia-Manero G; Rios MB; Cortes JE
J Clin Oncol; 2011 Nov; 29(32):4260-5. PubMed ID: 21990394
[TBL] [Abstract][Full Text] [Related]
19. Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication.
Lee MY; Park CJ; Cho YU; You E; Jang S; Seol CA; Seo EJ; Choi EJ; Lee JH
Cancer Immunol Immunother; 2020 Nov; 69(11):2223-2232. PubMed ID: 32474769
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia.
Inoue H; Taji H; Yamada K; Iriyama C; Saito T; Kato H; Yanada M; Yamamoto K; Matsukawa N
Intern Med; 2020 Oct; 59(19):2419-2421. PubMed ID: 32611965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
